XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST)

XTX Topco Ltd boosted its position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 570.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 160,807 shares of the company’s stock after purchasing an additional 136,818 shares during the quarter. XTX Topco Ltd owned 0.37% of Tempest Therapeutics worth $134,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Tempest Therapeutics during the fourth quarter valued at approximately $36,000. Geode Capital Management LLC lifted its stake in Tempest Therapeutics by 42.7% in the third quarter. Geode Capital Management LLC now owns 220,067 shares of the company’s stock valued at $308,000 after buying an additional 65,826 shares in the last quarter. Finally, Versant Venture Management LLC bought a new position in Tempest Therapeutics in the fourth quarter valued at approximately $2,927,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on TPST shares. HC Wainwright reaffirmed a “neutral” rating and issued a $16.00 price target on shares of Tempest Therapeutics in a research note on Thursday, April 10th. Scotiabank reaffirmed a “sector perform” rating and issued a $9.00 price target (up previously from $7.00) on shares of Tempest Therapeutics in a research note on Thursday, April 10th.

Tempest Therapeutics Stock Down 6.3 %

Shares of TPST stock opened at $7.34 on Wednesday. The company’s fifty day simple moving average is $9.18 and its 200-day simple moving average is $11.10. The firm has a market cap of $25.83 million, a PE ratio of -4.80 and a beta of -2.34. Tempest Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $49.27.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($4.03) EPS for the quarter, missing analysts’ consensus estimates of ($3.12) by ($0.91). The firm had revenue of $0.49 million for the quarter. On average, equities analysts predict that Tempest Therapeutics, Inc. will post -1.39 earnings per share for the current fiscal year.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.